Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Doctors explain if Berberine, dubbed “Nature’s Ozempic,” can really help with menopause weight loss. Here’s what to know.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...